ICON Announces Launch of Government and Public Health Solutions to Support Global Public Health
April 03 2018 - 7:00AM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced the
rebranding of their acquired ClinicalRM division into ICON
Government and Public Health Solutions (GPHS). ICON GPHS provide
full service clinical development and staffing services across
multiple agencies in the US Government, Global Non-Government
Organizations (NGOs), Academic Institutions and others in the
global health space, and have extensive experience working with
multi-national public health organizations.
Following ICON’s acquisition of ClinicalRM in 2016, the rebrand
demonstrates ICON’s commitment to solving global health issues
through enhancing capabilities in vaccines and infectious diseases.
With extensive experience supporting over 200 clinical vaccine
trials in over 40 countries worldwide, ICON is building a legacy in
supporting global public health, and is recognised as a qualified
provider for the Bill and Melinda Gates Foundation.
“The rebrand of ClinicalRM to ICON Government and Public Health
Solutions will both extend and solidify ICON’s offering to
government services and all those in the global health arena,”
commented Dr. James F. Cummings, President ICON Government and
Public Health Solutions. “It will also help ICON to further
leverage our extensive network in Africa, Asia and the Americas, to
help solve some of the most pressing global health challenges we
face today.”
ICON’s Government and Public Health Solutions will continue to
support US Federal Research, the Public Health Sector including
NGOs, to serve a common mission of generating new and safe medical
products for federal and commercial clients worldwide. ICON GPHS
provides expertise across basic and applied research, infectious
and neglected tropical diseases, oncology, vaccines development and
testing the response to biothreats.
ICON is widely recognised in the industry, with awards including
‘Best in Class’ CRO in vaccine research by the World Vaccine
Congress in 2017 and 2014 and has been commended or shortlisted for
this award consistently over the past 6 years. ICON was also
awarded Best Contract Research Organisation in the 2017 Scrip
Awards.
To learn more about ICON’s Government and Public Health
Solutions, please visit: www.iconplc.com/GPHS
About ICON plc ICON plc is a global provider of
outsourced drug development services to biopharma, medical device,
government, biosimilar and generic organisations. The company
specialises in the strategic development, management and analysis
of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in
Dublin, Ireland, ICON currently, operates from 98 locations in 38
countries and has approximately 13,250 employees.
Further information is available at: www.iconplc.com/
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180403005674/en/
For ICONWeber ShandwickOlivia Pimenta+44 (0)207
067 0557OPimenta@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2024 to May 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From May 2023 to May 2024